Dr. Reddy's shares rise 3% on buying Haleon’s nicotine gum biz; here’s what brokerages say
The pharma major has agreed to acquire Haleon Plc’s Nicotinell and related portfolio outside of the U.S., for 500 million pounds.
The pharma major has agreed to acquire Haleon Plc’s Nicotinell and related portfolio outside of the U.S., for 500 million pounds.
The BSE Sensex and Nifty50 are likely to open lower on Thursday, tracking soft cues from global peers and negative trend at Gift Nifty.
The stellar run continues post-Covid as promoters reap benefits of growth in India and new launches in key markets.
The revenue witnessed 29% growth at ₹6,738.4 crore in the Q1 of FY24, against ₹5,215.4 crore YoY, driven by sales in North America, emerging markets and Europe.
The pharma major received “zero observations” post the USFDA pre-approval inspection (PAI) and a routine GMP inspection at the Andhra Pradesh facility
India’s life sciences R&D is undergoing a sea change. Given the huge risks and investments involved, can India taste success in innovative medicine, therapy and diagnostic tools?
Dr. Reddy's posted a consolidated net profit of ₹1,187.6 crore in Q1FY23, registering a yearly growth of 108.05% and 1,257.25% on a quarterly basis.
Torrent Pharma will acquire Styptovit-E, Finast, Finast-T, and Dynapress brands from Dr Reddy’s Laboratories.
Revenue of the pharma company rose 15% year-on-year to ₹5,437 crore in the fourth quarter.
The BSE Sensex ended 296 points higher at 57,420, and the NSE Nifty surged 82.5 points, led by Tech Mahindra, Dr. Reddy's, Power Grid, and Sun Pharma.